Mechanisms of Antimicrobial Treatment in Human Diseases

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: 30 December 2024 | Viewed by 1354

Special Issue Editor

Special Issue Information

Dear Colleagues,

Antibiotics represent one of the most important discoveries of the last century, saving billion of lives following their introduction in clinical practice. Since the discovery of the first antimicrobial molecule, however, the emergence of antimicrobial resistance has been reported in several bacterial species. At the present, antimicrobial resistance represents a serious threat for public health, and infections due to multidrug-resistant (MDR) microorganisms represent one of the most important causes of death worldwide. In this context, the emergence and diffusion of MDR bacteria posed several limitations in the treatment of infections due to these microorganisms, thus requiring novel approaches to treat infections especially in critically ill patients. In recent years, the introduction of new antibiotics created the availability of new therapeutic strategies to treat infections sustained by microorganisms with a broad spectrum of resistance. At the same time, different points remain open for discussion regarding the optimal usage of new and old molecules, especially in the treatment of difficult-to-treat (DTR) infections caused by MDR bacteria. Although different steps have been taken in recent years, different questions remain unanswered regarding the optimal usage of different molecules and the correct pharmacokinetic/pharmacodynamic targets in clinical practice. In this Special Issue, we intend to focus on the appropriate use of antimicrobials with particular focus on the new molecules with action on MDR bacteria. We intend to collect original research articles, short communications, or review articles regarding the mechanisms of actions, the optimal administration of different antimicrobial molecules for the treatment of DTR due by MDR bacteria, and the emergence of new traits of resistance.

Dr. Paolo Gaibani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multidrug resistance
  • epidemiology
  • novel antimicrobial resistance traits

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 4149 KiB  
Communication
Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria
by Russell E. Lewis, Marta Palombo, Erica Diani, Benedetta Secci, Davide Gibellini and Paolo Gaibani
Cells 2024, 13(16), 1315; https://doi.org/10.3390/cells13161315 - 6 Aug 2024
Viewed by 990
Abstract
We investigated the activity of cefiderocol/β-lactamase inhibitor combinations against clinical strains with different susceptibility profiles to cefiderocol to explore the potentiality of antibiotic combinations as a strategy to contain the major public health problem of multidrug-resistant (MDR) pathogens. Specifically, we evaluated the synergistic [...] Read more.
We investigated the activity of cefiderocol/β-lactamase inhibitor combinations against clinical strains with different susceptibility profiles to cefiderocol to explore the potentiality of antibiotic combinations as a strategy to contain the major public health problem of multidrug-resistant (MDR) pathogens. Specifically, we evaluated the synergistic activity of cefiderocol with avibactam, sulbactam, or tazobactam on three of the most “Critical Priority” group of MDR bacteria (carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii). Clinical isolates were genomically characterized by Illumina iSeq 100. The synergy test was conducted with time-kill curve assays. Specifically, cefiderocol/avibactam, /sulbactam, or /tazobactam combinations were analyzed. Synergism was assigned if bacterial grow reduction reached 2 log10 CFU/mL. We reported the high antimicrobial activity of the cefiderocol/sulbactam combination against carbapenem-resistant Enterobacterales, P. aeruginosa, and A. baumannii; of the cefiderocol/avibactam combination against carbapenem-resistant Enterobacterales; and of the cefiderocol/tazobactam combination against carbapenem-resistant Enterobacterales and P. aeruginosa. Our results demonstrate that all β-lactamase inhibitors (BLIs) tested are able to enhance cefiderocol antimicrobial activity, also against cefiderocol-resistant isolates. The cefiderocol/sulbactam combination emerges as the most promising combination, proving to highly enhance cefiderocol activity in all the analyzed carbapenem-resistant Gram-negative isolates, whereas the Cefiderocol/tazobactam combination resulted in being active only against carbapenem-resistant Enterobacterales and P. aeruginosa, and cefiderocol/avibactam was only active against carbapenem-resistant Enterobacterales. Full article
(This article belongs to the Special Issue Mechanisms of Antimicrobial Treatment in Human Diseases)
Show Figures

Figure 1

Back to TopTop